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Aberrant activation of embryonic signaling pathways is frequent in pancreatic ductal adenocarcinoma (PDA),
making developmental regulators therapeutically attractive. Here we demonstrate diverse functions for pancreatic
and duodenal homeobox 1 (PDX1), a transcription factor indispensable for pancreas development, in the progression
from normal exocrine cells to metastatic PDA. We identify a critical role for PDX1 in maintaining acinar cell
identity, thus resisting the formation of pancreatic intraepithelial neoplasia (PanIN)-derived PDA. Upon neoplastic
transformation, the role of PDX1 changes from tumor-suppressive to oncogenic. Interestingly, subsets of malignant
cells lose PDX1 expression while undergoing epithelial-to-mesenchymal transition (EMT), and PDX1 loss is asso-
ciated with poor outcome. This stage-specific functionality arises from profound shifts in PDX1 chromatin occu-
pancy from acinar cells to PDA. In summary, we report distinct roles of PDX1 at different stages of PDA, suggesting
that therapeutic approaches against this potential target need to account for its changing functions at different stages
of carcinogenesis. These findings provide insight into the complexity of PDA pathogenesis and advocate a rigorous
investigation of therapeutically tractable targets at distinct phases of PDA development and progression.
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Pancreatic ductal adenocarcinoma (PDA) is the third lead-
ing cause of cancer-related mortality in the United States
and is slated to become the second by the end of this dec-
ade (Rahib et al. 2014). Despite recent therapeutic advanc-
es, the 5-year survival remains an abysmal 8% (Siegel
et al. 2016). Consequently, understanding the molecular
mechanisms of disease evolution and progression is im-
perative for developing novel therapeutic strategies.
PDA is thought to progress through a series of precursor
lesions termed pancreatic intraepithelial neoplasia
(PanIN) (Hruban et al. 2000). Consistent with >90% of
PDA containing KRAS oncogenic mutations (Bailey
et al. 2016), mutant KRAS appears to be responsible for
PDA initiation. Mouse models expressing oncogenic
Kras throughout the pancreatic parenchyma faithfully re-
capitulate the human disease with PanIN formation and
progression to adenocarcinoma (Aguirre et al. 2003;
Hingorani et al. 2003, 2005). Although its duct-like mor-
phology suggests a ductal epithelial origin, recent data
demonstrate that duct cells are mostly refractory to
Kras-induced transformation, while PanIN lesions readily
arise frommature acinar cells (De La O et al. 2008; Habbe
et al. 2008; Kopp et al. 2012). The apparent morphologic
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transition of acinar cells to duct cells mimics a process as-
sociated with pancreatic wound healing, known as acinar-
to-ductal metaplasia (ADM). Following injury, in condi-
tions such as chronic pancreatitis, acinar cells transdiffer-
entiate to formmetaplastic ducts, gaining progenitor-like
properties (Miyamoto et al. 2003). Once the insult has
subsided, it is hypothesized that metaplastic ducts prolif-
erate and differentiate back into acinar cells, allowing for
repopulation of the exocrine pancreas. Oncogenic KRAS
can initiate ADM but hijacks the healing process by
blocking acinar redifferentiation and promoting a transi-
tion from metaplasia to PanIN (Morris et al. 2010).
Pancreatic and duodenal homeobox 1 (PDX1) is a tran-
scription factor essential for pancreas development (Jons-
son et al. 1994; Offield et al. 1996). Initially expressed in
the pancreatic anlage, it is required for differentiation of
all pancreatic cell lineages (Jonsson et al. 1994; Offield
et al. 1996; Holland et al. 2002; Hale et al. 2005; Gannon
et al. 2008). PDX1 expression persists at high levels in β
cells, where it is required for efficient insulin gene tran-
scription (Ohlsson et al. 1993; Ahlgren et al. 1998;Holland
et al. 2002), but is maintained at lower levels in exocrine
cells (Guz et al. 1995; Wu et al. 1997) where its function
has not been thoroughly investigated. Pdx1 is up-regulat-
ed in the adult pancreas in ADM induced by constitutive
overexpression of TGFα (Song et al. 1999). Likewise, ex-
pression of oncogenic KRAS in the pancreatic parenchy-
ma leads to neoplasia with increased expression of
PDX1 (Hingorani et al. 2003). PDX1 up-regulation in these
models suggests its possible role inmetaplasia and neopla-
sia. Indeed, PDX1 has been proposed as an oncogene, as its
overexpression in PDA cell lines increases proliferation,
invasiveness, and growth in soft agar (Liu et al. 2008).
However, a more recent large-scale study suggests that
PDX1 loss is associated with a more aggressive subtype
of PDA (Bailey et al. 2016). With these seemingly contra-
dictory findings in mind, we set out to clarify the roles
of PDX1 in the adult exocrine pancreas and its associated
diseases, examining organ homeostasis, pancreatitis, tu-
morigenesis, and PDA progression using an acinar cell-
specific Pdx1 conditional knockout mouse and RNAi
approaches.
Results
Pdx1maintains acinar cell identity
To analyze PDX1 expression at the early stages of pan-
creatic neoplasia, we used the Ptf1aCre/+;KrasLSL-G12D/+;
Trp53f/+ (KPC) mouse model of PDA. These animals har-
bor PanINs by 4–6 wk of age that progress to well-differen-
tiated PDA by 18–24 wk of age. We observed uniformly
strong PDX1 expression in ADM and PanIN lesions (Sup-
plemental Fig. S1A) and low-level expression in acinar
cells in both adult murine and human pancreata (Supple-
mental Fig. S1A–C). Thus, increased PDX1 expression
correlates with transformation. Pdx1 expression in em-
bryonic acinar cells has been noted (Offield et al. 1996),
but its low-level expression in adult acinar cells has
been largely dismissed. Considering prior work pointing
to acinar cells as progenitors for PanIN-derived PDA, we
were interested in whether PDX1 performs critical func-
tions in acinar cells.
To address Pdx1 function in acinar cells, we used
Ptf1aCreERTM/+;Pdx1f/f animals to ablate Pdx1 specifically
from adult acinar cells via tamoxifen administration (Pan
et al. 2013). Eight-week-old to 12-wk-old Ptf1aCreERTM/+
(control) and Ptf1aCreERTM/+;Pdx1f/f animals were tamox-
ifen-treated to induce recombination and sacrificed 2 wk
later. Pancreata from control animals appeared histo-
logically normal, with PDX1 expression high in islet
and low in acinar, centro-acinar, and ductal cells (Supple-
mental Fig. S2A). In insulin-producing β cells, PDX1
maintains cell function, and its depletion erodes their
differentiation status (Puri et al. 2014). Pdx1 ablation
from acinar cells did not induce any overt exocrine ab-
normalities despite an increase in both apoptosis and
proliferation (Supplemental Fig. S2A). We then treated co-
horts of mice with cerulein, a cholecystokinin analog
that stimulates transient ADM in wild-type pancreata.
Adult Ptf1aCreERTM/+ and Ptf1aCreERTM/+;Pdx1f/f animals
were treated with tamoxifen followed by cerulein to
induce ADM. One day after cerulein treatment,
Ptf1aCreERTM/+;Pdx1f/f mice presented with enhanced aci-
nar dedifferentiation accompanied by increased apoptotic
activity (Fig. 1A). Lesions in both wild-type and Pdx1f/f
pancreata were proliferative, as shown by Ki67-positive
staining. Metaplastic lesions resolved within 7 d after cer-
ulein in control animals, but Ptf1aCreERTM/+;Pdx1f/f ani-
mals maintained widespread ADM and had a severe
reduction in the pancreas to body mass ratio, demonstrat-
ing that ADM derived from acinar cells require PDX1 for
redifferentiation (Fig. 1A; Supplemental Fig. S2C). Of
note, the profound loss of acinar cells in the cerulein-treat-
ed Ptf1aCreERTM/+;Pdx1f/f pancreata 7 d after treatment
makes the PDX1 expression in the normal ducts not af-
fected by the Ptf1aCreERTM/+ driver especially evident
(Fig. 1A). These results highlight that it is the acinar
cell-derived metaplastic ducts that are uniquely capable
of regenerating the damaged organ. Consistent with
these in vivo data, acinar cell explants derived from
Ptf1aCreERTM/+;Pdx1f/fmice treated with tamoxifen trans-
differentiated to ductal structures more rapidly than
Ptf1aCreERTM/+-derived explants in response to cerulein
treatment (Supplemental Fig. S2B). Collectively, PDX1
appears to both maintain and re-establish acinar differen-
tiation in injury models.
Next we sought to determinewhether Pdx1 contributes
to Kras-induced transformation. To address this, we
crossed KrasLSL-G12D/+ mice with Ptf1aCreERTM/+;Pdx1f/f
animals. Eight-week-old to 12-wk-old Ptf1aCreERTM/+;
KrasLSL-G12D/+;Pdx1f/f and Ptf1aCreERTM/+;KrasLSL-G12D/+
control animals were tamoxifen-treated and sacrificed
6 wk after treatment. As expected, controls expressing
only KrasG12D in their acinar cells formed infrequent
ADM lesions (von Figura et al. 2014a). In contrast, the ad-
ditional ablation of Pdx1 showedwidespread loss of acinar
cells, accompanied by extensive formation of ductal le-
sions (Fig. 1B). Pdx1-null lesions showed histological and
molecular characteristics of PanIN, such as highly acidic
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Figure 1. Pdx1 loss accelerates inflammation and oncogene-induced ductalmetaplasia. (A) Acinar cells lacking Pdx1 undergomore rapid
and extensive dedifferentiation. Eight-week-old to 12-wk-old Ptf1aCreERTM/+ andPtf1aCreERTM/+;Pdx1f/fmicewere treatedwith tamoxifen.
Three days following tamoxifen administration, animals were treated with saline or cerulein for 7 d and allowed to recover for 1 or 7
d. RepresentativeH&E stainings at the indicated time points are shown. PDX1 immunohistochemistrywas performed to confirm efficient
Pdx1 ablation. Immunohistochemistry for cleaved caspase 3 and Ki67 measured apoptosis and cell proliferation, respectively. (B) Eight-
week-old to 12-wk-old Ptf1aCreERTM/+;KrasLSL-G12D/+ and Ptf1aCreERTM/+;KrasLSL-G12D/+;Pdx1f/fmice were treated with tamoxifen and eu-
thanized 6 wk later. Two hours prior to euthanasia, mice were injected intraperitoneally with BrdU. Representative H&E staining is
shown. Alcian blue staining highlights the mucinous region, whereas PDX1 immunohistochemistry demonstrates efficient Pdx1 dele-
tion. Immunohistochemistry for cleaved caspase 3 and BrdU measured apoptosis and cell proliferation, respectively. (C ) Ductal lesions
(ADMand PanIN 1–3) were counted and graded in 10 10× fields from three pancreata of each genotype and time point. Sampleswere blind-
ed. Shown are the percentages of specific grades compared with the total counted.
PDX1 function in pancreatic cancer
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mucin content marked by positive Alcian blue staining
(Fig. 1B), but were less proliferative, as shown by BrdU in-
corporation. Thus, the accelerated transformation in
Pdx1-null animals appeared to be due to rapid erosion of
acinar differentiation rather than expansion through in-
creased cell proliferation. No differences were observed
in apoptosis. In line with their accelerated initial transfor-
mation, pancreata from Pdx1-null mice had rapidly pro-
gressed past ADM to form high-grade PanIN (PanIN 2/3)
at 4 and 12mo of age (Fig. 1C) comparedwith age-matched
controls. Collectively, our results point to a dynamic
pattern of Pdx1 expression that maintains acinar cell
differentiation during pancreatic damage and oncogenic
Kras-driven transdifferentiation. Acinar redifferentia-
tion can then be overridden by KrasG12D expression or
blocked by Pdx1 ablation, with the two synergizing to
enhance the overall amount of transformation (Supple-
mental Fig. S2D).
To gain mechanistic insight into how Pdx1 inhibits
ADM, we performed genome-wide transcriptome profil-
ing. Acinar cells were isolated from Ptf1aCreERTM/+ or
Ptf1aCreERTM/+;Pdx1f/f animals treated with tamoxifen
and incubated with TGFα to induce ADM. Cells were har-
vested at days 0, 1, 2, and 3 following TGFα treatment, and
gene expression was analyzed by RNA sequencing (RNA-
seq). At day 0, even before evident ductalmetaplasia, Pdx1
ablation initiated destabilization of acinar identity (Fig.
2A). Pathway enrichment analysis revealed several aci-
nar-specific genes to be down-regulated (e.g., Cpa3),
whereas genes defining duct cells, such as Cftr, were up-
regulated in Pdx1-null acinar cells, suggesting that Pdx1
may function as a “gatekeeper” of acinar identity (Fig.
2A; Supplemental Fig. S3). At days 1 and 2, when acinar
cells underwent initial dedifferentiation, several genes be-
longing to pancreatic secretion pathways were differen-
tially regulated in Pdx1-null acinar cells (Fig. 2B,C).
Specifically, genes that define themature acinar cell state,
such asAmy2b,Cpa1,Cpb1,Cel, andCela2a, were down-
regulated in Pdx1-null acinar cells, pointing toward accel-
erated erosion of the mature acinar state. In addition,
genes regulating ECM–receptor interactions, actin cyto-
skeleton, and proteoglycans were differentially expressed.
Interestingly, at day 3, when the acinar ductal reprogram-
ming process had concluded, differentially regulated
genes belonged to the networks that support tumorigene-
sis, such as cell cycle, p53 signaling, and cytokine/recep-
tor interactions (Fig. 2D). These findings shed light on
how Pdx1 function promotes acinar identity in wild-
type acinar cells and how it may regulate aspects of redif-
ferentiation to resolve ADM. Importantly, longer-term
loss of Pdx1 promotes proliferative signals that may com-
plement oncogenic Kras in the transition from ADM to-
ward PanIN and PDA.
Opposing roles of Pdx1 in tumor maintenance
Pdx1 ablation promotes acinar dedifferentiation. Howev-
er, prior work demonstrated a profound increase in
PDX1 expression in neoplastic lesions, indicating that
its function may change during cellular transdifferentia-
tion and tumorigenesis. To test this, we attenuated
Pdx1 expression inmouse PDA-derived cell lines. Two in-
dependent PanIN-derived PDA tumor lines were trans-
fected with constructs expressing doxycycline (dox)-
inducible Pdx1 targeted or control shRNAs. In both cell
lines, dox treatment significantly reduced PDX1 expres-
sion compared with controls (Supplemental Fig. S4A,
top). Pdx1 deficiency blocked cell growth, suggesting pro-
tumorigenic functions of PDX1 (Supplemental Fig. S4A,
bottom), consistent with previous reports (Wu et al.
2014). As PDA can originate from neoplastic lesions other
than PanIN, we asked next whether Pdx1 has analogous
oncogenic activities in PDA emerging from PanIN or
intraductal papillary mucinous neoplasia (IPMN). Six dif-
ferent primary tumor cell lines were analyzed, including
three isolated from PanIN-derived PDA from Ptf1aCre/+;
KrasLSL-G12D/+ mice and three cell lines established from
IPMN-derived PDA from Ptf1aCre/+;KrasLSL-G12D/+;Brg1f/f
mice. Reducing Pdx1 expression using siRNA in these
PDA lines impaired cell survival (Fig. 2E), demonstrating
that PDX1maintains tumorigenicity ofmalignant cells ir-
respective of their origin (von Figura et al. 2014a).
We next addressed whether PDX1 has similar tumor-
promoting activities in human PDA. We compared
PDX1 expression in several human PDA-derived tumor
lines with HPDE, a human duct cell line that expresses
low levels of PDX1, and human islets, which have high
PDX1 expression. Most PDA cell lines expressed PDX1
at levels significantly higher than HPDEs but lower than
islets (Supplemental Fig. S4B), emphasizing thatmoderate
PDX1 up-regulation accompanies exocrine cell transfor-
mation. To assess whether PDX1 up-regulation influ-
enced tumor cell survival, we reduced PDX1 expression
using siPDX1 in 13 different human PDA lines. Similar
to the mouse PDA lines and consistent with previous
studies (Yu et al. 2016), decreasing PDX1 expression led
to reduction in cellular growth or survival, albeit at vari-
able levels (Fig. 2F). To elucidate the protumorigenic func-
tions of PDX1 in greater detail, we performed cell
proliferation and apoptosis assays. In four independent hu-
manPDA lines, siPDX1 reduced cell proliferation (Fig. 3A)
and increased cleaved caspase 3/7 activity (Fig. 3B). We
conclude that PDX1 has two apparent protumorigenic
functions in established tumors: maintenance of cellular
proliferation and inhibition of apoptosis.
Another important characteristic of tumor cells is their
ability to grow in anchorage-independent conditions. At-
tenuating PDX1 expression in three-dimensional (3D) cul-
ture conditions resulted in reduced colony formation,
indicating that PDX1 maintains the transformed pheno-
type of PDA cells (Fig. 3C). To examine PDX1 function
in vivo, we stably transduced two human PDA lines
with lentivirus expressing shControl or shPDX1 and
transplanted them subcutaneously into immunocompro-
mised NSG mice. Tumor size was significantly lower in
shPDX1-expressing cells (Fig. 3D,E) due to reduced cell
proliferation and increased apoptosis (Fig. 3F–H). Thus,
in contrast to its role in resisting acinar transformation,
PDX1 promotes tumorigenicity of PDA cells (Supplemen-
tal Fig. S4C).
Roy et al.
2672 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on March 7, 2017 - Published by genesdev.cshlp.orgDownloaded from 
To gain mechanistic insight into how PDX1 loss reduc-
es tumorigenicity, we performed genome-wide trans-
criptome analysis of four different human PDA lines
transfected with either control or PDX1 siRNA (Supple-
mental Fig. S5A). Several geneswere consistently differen-
tially regulated between control and PDX1 siRNA-treated
cells, but the extent towhich gene expressionwas affected
varied significantly. Gene set enrichment analysis (GSEA)
on differentially expressed genes revealed several onco-
genic pathways that were perturbed, the most prominent
among them being the KRAS signaling pathway. In three
out of four lines, genes down-regulated by oncogenic
KRAS or its downstream effectors, RAF/MEK, were en-
riched in PDX1 siRNA-treated cells, suggesting that the
KRAS signaling pathway is affected by PDX1 knockdown
(Fig. 4A,B). Surprisingly, when theMAPKpathways down-
stream from KRAS were surveyed, we found that PDX1
down-regulation consistently resulted in higher pERK lev-
els (Supplemental Fig. S5B,C). It is possible that up-regula-
tion of pERK is a compensatory feedbackmechanism that
tumor cells activate in order to overcome the stress in-
duced by PDX1 knockdown, which is accompanied by
up-regulation of proapoptotic genes and attenuation of
cell cycle genes associated with proliferation (Fig. 4C).
We then focused on apoptosis and cell cycle pathways to
identify key factors in these pathways that may be
Figure 2. PDX1 regulates distinct sets of genes in acinar cells undergoing ADM. (A–D) Acinar cells were isolated from tamoxifen-
treated Ptf1aCreERTM/+ (n = 3) and Ptf1aCreERTM/+;Pdx1f/f (n = 3) mice. Cells were treated with TGFα to induce in vitro ADM. At days
0, 1, 2, and 3, cells were harvested, and whole-genome transcriptome profiling was done by RNA-seq. The graphs at the left show differ-
entially expressed genes between Pdx1 wild-type and Pdx1-null acinar cells at each time point. The tables at the right show pathway
analyses of genes differentially regulated at least ±1.5-fold. The top 10 pathways from each data set are shown along with their respec-
tive P-values. Pathways of interest are color-coded, and genes that belong to those pathways are listed. Green indicates genes down-
regulated in Pdx1-null cells, and red indicates up-regulated genes in Pdx1-null cells. (E, left) Quantitative PCR analysis of Pdx1 in
mouse PDA-derived cell lines transfected with control or Pdx1 siRNA. (Right) Relative survival of cells following siRNA-mediated
Pdx1 knockdown in mouse PDA-derived cell lines. (F, top) Quantitative PCR analysis of PDX1 in human PDA-derived cell lines trans-
fected with control or PDX1 siRNA. (Bottom) Relative survival of cells following siRNA-mediated PDX1 knockdown in human PDA-
derived tumor cell lines.
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regulated by PDX1. Although the gene sets were heteroge-
neous between cell lines, several geneswere up-regulated/
down-regulated in at least three out of four cell lines
analyzed. Among them was Aurora kinase A (AURKA),
a serine/threonine protein kinase that promotes G2/M
transition during the cell cycle. We further confirmed
that PDX1 positively regulates AURKA expression by
quantitative PCR, suggesting a defect in G2–M cell cycle
transition that may lead to reduced proliferation of
cells following PDX1 knockdown (Fig. 4D). Several
apoptosis-regulating factors were also differentially ex-
pressed between control and PDX1 siRNA cells, including
the proapoptotic factors Caspase 3, Diablo, FADD, FAS,
TNFRSF10B, and TNFSF10 and anti-apoptotic protein
XIAP (Supplemental Fig. S5D). Quantitative PCR showed
that TNFRSF10B and Diablo were up-regulated in several
PDA lines following PDX1 siRNA treatment, suggesting
that PDX1 attenuation triggers a signaling cascade predis-
posing cells to undergo apoptosis (Fig. 4E,F). Thus, PDX1
enhances the tumorigenicity of PDA cells by controlling
several critical pathways that regulate cell proliferation
and apoptosis.
Profound shifts in PDX1 chromatin occupancy
in acinar cells vs. PDA
Our data demonstrate that, during the earliest transitional
stages from acinar cells toward neoplasia, Pdx1 restrains
neoplastic transformation. In contrast, Pdx1 maintains
the tumorigenic properties of transformed PDA cells (Sup-
plemental Fig. S4C), a shift that is accompanied by robust
changes in gene expression profiles. To determine how
Pdx1 performs these discordant functions in normal and
transformed cells, we performed PDX1ChIP-seq (chroma-
tin immunoprecipitation [ChIP] combined with high-
throughput sequencing) profiling on primary mouse aci-
nar cells and mouse PDA-derived cell lines (Fig. 5A). Re-
gion gene association studies revealed that PDX1 binds
mostly to intergenic regulatory regions (Fig. 5B; Supple-
mental Fig. S6A). Notably, there was minimal overlap be-
tween PDX1-bound regions in acinar and PDA cells,
indicating that PDX1 regulates distinct gene sets in pri-
mary and transformed cells (Fig. 5C). Pathway enrichment
analysis of PDX1-bound regions revealed that, in acinar
cells, PDX1 binds to genes associated with endocrine
Figure 3. PDX1 maintains tumorigenicity of human PDA cells in vivo. (A) Relative cell proliferation of the indicated human PDA-de-
rived cell lines at 1, 3, and 5 d following transfectionwith control or PDX1 siRNA. (B) Relative caspase 3/7 activity of the indicated human
PDA-derived cell lines 24 h after transfection with control or PDX1 siRNA. (C ) Relative survival of cells in three dimensions following
siRNA-mediated PDX1 knockdown in human PDA-derived tumor cell lines. HPAF-II (D) and Panc.8 (E) cells expressing either control
shRNA or shRNA targeting PDX1were subcutaneously injected into NSGmice, and tumor growth was measured. Mice were sacrificed
4wk after inoculation, and tumor sizes weremeasured. (F ) H&E and costaining of Ki67, cleaved caspase 3, andDAPI of tumors obtained in
D and E. Quantification of Ki67-positive cells (G) and the cleaved caspase 3-positive area (H) of tumors obtained in D and E.
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development and differentiation, embryonic develop-
ment, and epithelial cell differentiation (Fig. 5E, top).
Examples of the latter include Nr5a2, FoxA2, and One-
cut1, transcription factors driving pancreatic develop-
ment. In addition, PDX1 binding was enriched on Cela1,
Cela2, Cpa2, and Amy1, genes that define the acinar dif-
ferentiation state (Fig. 5D). In tumor cells, PDX1 bound
to genes in important networks regulating tumorigenesis,
including the E-cadherin stabilization pathway (associat-
ed with epithelial-to-mesenchymal transition [EMT]),
TNF-NFκβ, cellular response to TGFβ, and regulation
of ERBB signaling (Fig. 5E; bottom). For instance, PDX1
was uniquely bound to the MAPK pathway geneMap4k3
and the Wnt/β-catenin pathway component Prickle1 in
PDA cells but not acinar cells (Fig. 5D). PDX1 enrichment
in these regions correlates with active transcription of as-
sociated genes. Acinar-specific genes (such as Amy1 and
Cela1) display higherH3K4me3 andH3K27ac enrichment
in acinar cells compared with PDA cells (Supplemental
Fig. S6C,E,F). Conversely, PDA-specific genes (Map3k1,
Map4k3,Mapkapk2, andCdkn2b) exhibit an increased re-
pressive mark (H3K27me3) in acinar cells compared with
PDA cells (Supplemental Fig. S6D). These data highlight
an important regulatory shift in PDX1 function from
maintenance of an acinar-specific differentiation program
to promotion of oncogenic signaling in PDA. Motif analy-
sis revealed that PDX1-bound regions in acinar cells were
also enriched for transcription factors defining the pancre-
as differentiation state, such asHnf4a,Nkx6.1, Hnf1a, and
Hnf1β (Fig. 5F; Supplemental Fig. S6B). In contrast, inPDA,
motifswere enriched for somepancreasdifferentiation fac-
tors but also oncogenic transcription factors such as Gsc2,
Prrx2, Stat5, c-Jun, and c-Fos.
To show direct correspondence between PDX1 binding
and effects on gene expression, we next integrated RNA-
seq and ChIP-seq data (Fig. 5G). We examined the expres-
sion of genes bound by PDX1 in either acinar cells (Fig.
5G, top) or PDA cells (Fig. 5G, bottom) in four different
cell types: wild-type and Pdx1-null acinar cells and
wild-type and Pdx1 knockdown murine PDA cells. It is
evident from the analysis that the expression of genes
bound by PDX1 in either cell type is significantly differ-
ent between wild-type acinar and PDA cells. Also, genes
bound by PDX1 in acinar cells are differentially expressed
largely between wild-type and Pdx1-null acinar cells. On
the other hand, expression of genes bound by PDX1 in
PDA cells is mostly affected by Pdx1 depletion in PDA
cells, with only a fraction affected in acinar cells. The
dynamic changes in PDX1 binding to acinar-specify-
ing genes to oncogenic signaling pathways reveal an
Figure 4. PDX1 maintains a transcriptional landscape conducive to oncogenic Kras signaling. (A) GSEA of RNA-seq data from Supple-
mental Figure S5A.Genes differentially expressed at least ±1.5-fold between control siRNAand PDX1 siRNA-treated cells were compared
with gene set-defining oncogenic signatures. (B) Kras signature enrichment plots in humanPDA-derived cell lines transfectedwith control
or PDX1 siRNA. (C ) Cell cycle and apoptosis signature enrichment plots in human PDA-derived cell lines transfected with control or
PDX1 siRNA-treated cells. Quantitative PCR analysis ofAURKA (D), TNFRSF10B (E), andDIABLO (F ) in human PDA-derived cell lines
transfected with control or PDX1 siRNA.
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Figure 5. PDX1 dynamically switches its function between acinar cells and PDA. (A) PDX1 ChIP-seq was performed on acinar cells iso-
lated fromwild-typemice and themouse PDAcell lineNB-490. The heatmap shows enrichment of PDX1 binding in acinar and PDAcells.
(B) PDX1 ChIP-peak distribution across different genomic regions in primary acinar cells or PDA cells (NB490). (C ) Overlap in PDX1-
bound regions between acinar and PDA cells. (D) ChIP-seq signal tracks of PDX1 on the indicated genes in acinar and PDA cells. (E) Func-
tional categories of PDX1 putative target genes by using pathway enrichment analysis. The list shows the top 20 pathways enriched in
PDX1 ChIP-seq targets in acinar (top) and PDA (bottom) cells (F ) Sequence motifs identified by motif analysis of PDX1-bound regions
in acinar and PDA cells. (G) Heat map showing relative expression of genes bound by PDX1 in either acinar cells (top) or PDA cells (bot-
tom) in four different cells types: wild-type acinar cells, Pdx1-null acinar cells, wild-type mouse PDA cells, and PDA cells expressing
shRNA against Pdx1.
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important underlying mechanism of the context-depen-
dent roles of PDX1.
Distinct PDX1 expression levels in PDA subtypes
Recent next-generation sequencing analysis has revealed
that PDA is a conglomeration of four different subtypes
with distinct histopathological characteristics and dispa-
rate survival prognoses (Collisson et al. 2011; Bailey
et al. 2016). Interestingly, in the squamous subtype that
carries the worst prognosis, the PDX1 promoter is highly
methylated, suggesting epigenetic silencing of PDX1.
This seemingly contradictory finding led us to analyze
the expression pattern of pancreas lineage-specifying fac-
tors, including PDX1, in different PDA subtypes (Fig.
6A). Unsupervised expression clustering for these factors
revealed PDX1 to be highly expressed in the pancreatic
progenitor ADEX and immunogenic PDA subtypes but
observed at low levels in the squamous subtype (Fig. 6B).
We further confirmed the heterogeneous PDX1 expres-
sion pattern among PDA patients by immunohistochem-
istry (Fig. 6C). Furthermore, in two different cohorts that
encompassed all PDA subtypes, low PDX1 expression
was significantly associated with lower overall and dis-
ease-free survival (Fig. 6D; Supplemental Fig. S7A). How-
ever, PDX1 expression did not have any statistically
significant correlation with disease outcome in the pan-
creatic progenitor subclass, where patients display high
PDX1 (Supplemental Fig. S7B).
We also observed that genetically engineered mouse
models faithfully recapitulate heterogeneity in PDX1 ex-
pression (Fig. 6E). In some areas of PDA, expression was
very high (Fig. 6E, panel i), whereas others displayed a
complete lack of PDX1 expression (Fig. 6E, panel ii).
Thus, not only does PDX1 have distinct functions in aci-
nar versus cancer cells, but reduced PDX1 levels correlate
with the most aggressive squamous tumor type.
PDX1 activity regulates EMT
In contrast to our cell culture data, which suggest that re-
ducing PDX1 expression in established tumors would be
beneficial, patient data revealed that low-PDX1 patients
show worse survival. Metastasis to distant organs, rather
than primary tumor burden, is frequently the cause of
death in PDA patients (Yachida et al. 2010). Intriguingly,
the squamous subtype, which loses PDX1 expression, dis-
plays molecular characteristics of increased metastatic
Figure 6. Low PDX1 expression predicts poor PDA prognosis. Expression of transcription factors regulating pancreatic organogenesis (A)
and PDX1 (B) in four different pancreatic cancer subtypes based on the study by Bailey et al. (2016). (C ) Representative PDX1 staining in
human PDAwith low (panel i), intermediate (panel ii), and high (panel iii) PDX1 expression in infiltrating tumors. Normal ducts in panel i
and islets in panel ii stained positive for PDX1. (D) Kaplan-Meier survival curve of PDA patients with low or high PDX1 RNA expression.
n = 183. (E) Representative staining for PDX1/cytokeratin 19 in Ptf1aCre/+;KrasLSL-G12D/+;Trp53f/+ mouse pancreata showing variable ex-
pression (high [panel i] and low [panel ii]) of PDX1 in mouse tumor tissues. Solid arrowheads indicate regions that have reduced PDX1
expression.
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potential. We reasoned that, independent of its effects on
proliferation and survival, PDX1 down-regulation might
enhance tumor aggressiveness. EMT, where epithelial
cells lose epithelial marks in order to disseminate into a
vascular or lymphatic system, enhances metastasis (Kal-
luri and Weinberg 2009). To test whether PDX1 down-
regulation is part of the EMT program, we examined
two models: HGF (hepatocyte growth factor) treatment
of HPAF-II cells and TGFβ treatment of Panc.1 cells
(Song et al. 2010). As shown in Figure 7, both HGF and
TGFβ treatment induced EMT, accompanied by reduced
PDX1 expression (Fig. 7A,B). To further confirm the po-
tential role of Pdx1 in EMT in vivo, we used Ptf1aCre/+;
KrasLSL-G12D/+;Trp53f/+;R26YFP/+ animals. In these ani-
mals, cells expressing Cre recombinase were irreversibly
marked with YFP, thus allowing for detection of epitheli-
al-derived cancer cells that have undergone EMT and now
express mesenchymal markers; e.g., YFP/Vimentin-dou-
ble-positive. Similar to our in vitro observations, epitheli-
al cells that have converted to a mesenchymal state
exhibited low PDX1, supporting the notion that, in order
to undergo EMT, epithelial cells need to reduce PDX1 ex-
pression (Fig. 7C). Likewise, in matched tissue sections
from mouse PDA, invasive tumor cells displayed lower
PDX1 expression compared with adjacent PanIN lesions,
suggesting that PDX1 loss may confer a metastatic advan-
tage (Supplemental Fig. S8).
The observed functions of PDX1 in PDA maintenance
and metastasis appear contradictory. Primary tumor cells
require sustained PDX1 expression for survival but atten-
uate PDX1 expression as part of EMT and metastasis. To
reconcile these functions, we hypothesized that tumor
cells use mechanisms to compensate for PDX1 loss. To
identify such compensatory mechanisms, we generated
cell lines that are resistant toPdx1 knockdown. By serially
passaging PDA cells expressing dox-inducible Pdx1
shRNA grown continuously in dox, Pdx1 knockdown
cells grew out within weeks (Fig. 7D) and were as prolifer-
ative as the parental line, indicating that they have ac-
quired traits to resist Pdx1 loss.
To identify the mechanism by which these cells toler-
ate the absence of Pdx1, we performed BrU-seq (bromour-
idine [BrU] sequencing) to identify new transcripts
synthesized after acquiring resistance to reduced Pdx1
(Paulsen et al. 2014). Cells were treated with BrU to label
nascent RNA. Labeled RNA was precipitated with an
anti-BrdU antibody and sequenced. With the cutoff set
at 1.5-fold change in expression, we found 348 genes
differentially expressed between control and Pdx1 knock-
down, 569 genes differentially expressed between knock-
down and “grow out,” and 385 genes differentially
expressed between control and “grow out” cells. When
compared with each other, there was little overlap be-
tween each data set, suggesting that “grow out” cells ini-
tiate a unique program to become resistant to Pdx1
depletion (Fig. 7E). Pathway analysis revealed several
pathways that were enriched in “grow out” cells: “TGFβ
signaling,” “chromatin organization,” and “estrogen re-
sponse pathway” (Fig. 7F). Among them, “chromatin orga-
nization” was particularly interesting, as chromatin
remodeling is a frequent mechanism of chemoresistance.
Two-thirds of the genes comprising the “chromatin orga-
nization” pathwaywere found to be up-regulated in “grow
out” cells. Among them, we detected an overrepresenta-
tion of histones, suggesting transcriptional amplification
(Supplemental Fig. S9A). Interestingly, when genes differ-
entially expressed between “knockdown” and “grow out”
cells were used for GSEA for motif enrichment, theMYC-
binding motif was the only significantly enriched motif
(Fig. 7G), which was associated with enrichment of the
Myc regulatory network (Supplemental Fig. S9B). MYC
has been shown to induce transcriptional amplification
in tumor cells, which contributes to tumor maintenance
(Lin et al. 2012). Thus, we conclude that, at themetastasis
stage, tumor cells reduce Pdx1 to undergo EMT, tempo-
rarily sacrificing proliferative potential, and then use
MYC to revive cell growth. In KPC animals, uniform
MYC and PDX1 colocalization was observed consistently
in PanIN lesions (Fig. 7H). Interestingly, when PanINs had
progressed to PDA, there was a divergence of this coex-
pression pattern. We found two groups of tumors in KPC
animals: well differentiated and undifferentiated. Well-
differentiated tumors were PDX1-high and MYC-low,
whereas undifferentiated invasive tumors were MYC-
high and PDX1-low (Fig. 7I). This is consistent with hu-
man PDA, where metastasis-prone squamous subtype
cancers display MYC pathway activation, are PDX1-low,
and have mutations in chromatin modifier genes (Bailey
et al. 2016).
Discussion
PDX1 function in the adult pancreas is historically con-
sidered to be restricted to β cells (Ahlgren et al. 1998; Gan-
non et al. 2008; Gao et al. 2014). Despite this common
perception, prior studies have shown Pdx1 expression in
normal adult exocrine pancreata and increased expression
in PDA, observations that imply possible regulatory roles
of PDX1 in neoplastic development and progression (Roy
and Hebrok 2015). Our analysis indicates temporally dis-
tinct and even seemingly antagonistic functions of
PDX1 during maintenance of mature acinar differentia-
tion, injury-induced acinar regeneration, PanIN, PDA,
and metastasis. At the onset of oncogenic Kras-driven
transformation, PDX1 restrains acinar cells from transdif-
ferentiating into ductal cells, thus acting as a “tumorigen-
esis-suppressor.” In contrast, PDX1 assumes a tumor-
promoting role when ADM lesions progress toward neo-
plasia and into the malignant state. In cancer cells,
PDX1 supports the malignant phenotype by controlling
a distinct group of genes compared with normal acinar
cells, suggesting that not only the level of expression but
redirected binding to specific regulatory elements are crit-
ical aspects of its diverse activities. Finally, in a subset of
epithelial tumor cells, PDX1 loss promotes EMT and me-
tastasis to distant organs (Fig. 7J).
The roles of PDX1 during embryogenesis have been
studied extensively and show that it is expressed in all
pancreatic epithelial cells at the onset of organogenesis
Roy et al.
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Figure 7. PDX1 loss is associated with EMT. (A) Quantitative PCR analysis of E-cadherin, Vimentin, and PDX1 expression in HPAF-II
cells treated with either vehicle or HGF. (B) Quantitative PCR analysis of E-cadherin, Vimentin, Snail1, and PDX1 expression in Panc.1
cells treated with either vehicle or TGFβ. (C ) Fluorescent images of lineage-labeled cells derived from pancreatic epithelium of Ptf1aCre/+;
KrasLSL-G12D/+;Trp53f/+;Rosa26LSL-YFP animals. Staining shows that epithelial cells that have undergone EMT (YFP-positive/Vimentin-
positive) have lost PDX1 expression. (D) Mouse PDA cells (NB490 sh1) were cultured and passaged with continual dox treatment for 3
wk to select for cells resistant to Pdx1 knockdown (“grow out”). Western blot analysis of PDX1 and HSP90 from “grow out” cells treated
with dox andNB490 sh1 cells left untreated (control) or treatedwith dox for 48 h (2-d dox). Growth curves ofNB490 sh1 cells left untreated
(control) or treated with dox and “grow out” cells treated with dox. (E) Overlap among differentially expressed genes (1.5-fold up or down)
in control, knockdown, and “grow out” cells. Purple curves link identical genes. The inner circle represents gene lists, where hits are ar-
ranged along the arc. Genes shared bymultiple lists are colored dark orange, and genes unique to a list are shown in light orange. (F ) Heat
map of enriched terms across differentially expressed genes (1.5-fold up or down) in the indicated groups, colored by P-value. (G) MYC-
binding signature enrichment plots in knockdown versus “grow out” cells. The plot shows the enrichment of MYC-binding targets in
“grow out” cells. (H) Immunofluorescence staining from a Ptf1aCre/+;KrasLSL-G12D/+;Trp53f/+ mouse showing colocalization of MYC
and PDX1 in PanIN. (I ) Immunofluorescence staining of a well-differentiated tumor from an 11-wk-old PDX1-Cre;KrasLSL-G12D/+;
Trp53R172H/+ mouse (top panels) and a poorly differentiated invasive tumor from a 28-wk-old PDX1-Cre;KrasLSL-G12D/+;Trp53R172H/+;
Rosa26LSL-YFPmouse (bottom panels). Yellowarrows highlight YFP-positive tumor cells, while yellowarrowheads highlight YFP-negative
stromal cells. (J) Model depicting PDX1 functions at different stages of pancreatic cancer tumorigenesis. At early stages, PDX1maintains
acinar identity and inhibits Kras-driven acinar dedifferentiation. In the later malignant stage, PDX1 maintains tumorigenicity of cells by
supporting cell proliferation and inhibiting apoptosis. During metastasis, malignant cells lose PDX1 expression to undergo EMT.
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(Jonsson et al. 1994; Offield et al. 1996). While PDX1 is re-
quired to establish the acinar cell lineage, only low-level
expression is detected in adult enzyme-producing cells
(Hale et al. 2005; Kodama et al. 2016). Thus, it was surpris-
ing that Pdx1 depletion in adult mice led to perturbations
in exocrine function (Holland et al. 2002). However, ec-
topic Pdx1 expression in progenitors induces abundant
ADM (Kawaguchi et al. 2002; Miyatsuka et al. 2006),
and Elastase-Cre-driven Pdx1 overexpression in exocrine
precursors triggers marked dysmorphogenesis in the exo-
crine pancreas (Heller et al. 2001). These studies indicate
that Pdx1 expression needs to be tightly controlled to
properly maintain adult acinar tissue functionality. Sup-
porting this notion, our data show that Pdx1 deletion in
mature acinar cells in the presence of oncogenic/inflam-
matory signals produces a phenotype comparable with ec-
topic overexpression in embryonic progenitor cells. Of
note, our analysis further suggests that once acinar identi-
ty is eroded,Pdx1 reactivation supports tumor progression
by controlling a distinct transcriptional program capable
of promoting neoplasia, the first indication that PDX1 ful-
fills different roles within the same cells but in the differ-
ent cellular contexts of homeostasis and disease.
The notion that a defined network of transcriptional
factors, such as Ptf1a,Mist1, andNr5a2, maintains acinar
integrity and impairs mutant Kras-driven ADM has been
described before (Shi et al. 2013; Flandez et al. 2014; von
Figura et al. 2014b; Krah et al. 2015). Our results indicate
that Pdx1 joins this list of “acinar differentiation” regula-
tors. Consistent with this idea, our RNA-seq analysis sug-
gests that PDX1 maintains acinar identity by direct
binding to regulatory elements of acinar differentiation
genes such as Amy1, Cela2, Cela1, and Cpa2. PDX1 ex-
erts its transcriptional activity through interaction with
distinct sets of coregulators, such as PBX1b and MEIS2,
in acinar cells (Swift et al. 1998). In future work, it will
be interesting to examine changes in the composition of
coregulators during ADM, PanIN, and PDA development
and whether this alters PDX1 binding to a diverse set of
target genes.
Our data indicate that a subset of human PDA, centro-
acinar, and ductal cells expresses PDX1, an observation
analogous to the results obtained in mice. Intriguingly,
in human PDA samples, PDX1 levels vary widely. Earlier
studies described either no correlation or high PDX1 to be
associated with poor prognosis (Koizumi et al. 2003; Park
et al. 2011). In contrast, using two different patient co-
horts, we show conclusively that low, not high, PDX1 ex-
pression is an independent predictor of poor disease-free
survival. Also, considering the heterogeneity of PDX1 ex-
pression in KPC mouse models and PDA subtypes, it is
possible that not all subtypes were included in the smaller
patient cohort size (n = 35 in Koizumi et al. 2003; n = 67 in
Park et al. 2011). Our analysis of a larger cohort, totaling
325 patients and representing all subgroups, may explain
the newly evident correlation between survival and
PDX1 expression.
Brunicardi and colleagues (Yu et al. 2016) had shown
previously that PDX1 knockdown reduces cell survival
in human PDA lines. We observed a similar effect, but
our examination of multiple PDA lines suggests that all
tumor cells are not equally vulnerable to PDX1 defi-
ciency. Based on our observation of disparate PDX1 levels
in different PDA patients harboring tumors of differing
subtypes, it is possible that the gene network intrinsic
to these various PDA subtypes likely predicts the re-
sponse to PDX1 knockdown.
The exact role of PDX1 in metastasis is hard to pin-
point. Prior work on a mouse model of PDA has revealed
that a subpopulation of PDX1+ cells has an inherent capac-
ity to metastasize (Ischenko et al. 2014). However, other
data together with our findings point to distinct PDX1 ac-
tivities in resident and metastatic PDA cells. One recent
study showed PDX1 to be down-regulated during EMT
(David et al. 2016). In vivo, metastatic lesions also exhibit
loss of nuclear PDX1 expression, further suggesting a pos-
sible regulatory role of PDX1 in EMT (Morton et al. 2008).
Similarly, we found that EMT in PDA attenuates PDX1
expression both in vitro and in vivo. PDX1 is known to ac-
tivate expression of the epithelial marker E-cadherin
(Marty-Santos and Cleaver 2016), supporting the sugges-
tion that its loss might be necessary for EMT. Consistent
with this notion, in the context of oncogenic Kras, our pre-
liminary analysis suggests that Pdx1-null animals display
more frequent delamination events and higher numbers of
circulating tumor cells compared with their wild-type
counterpart (data not shown). However, PDX1 overexpres-
sion is not sufficient to reverse EMT (Ischenko et al. 2014),
suggesting that PDX1 loss is associated with, andmay ini-
tiate, a broadly remodeled cancer phenotype.
Evidence for this hypothesis comes from selecting for
cells capable of expanding in the absence of Pdx1. In these
cells, we observed up-regulation of a Myc regulatory net-
work, which is negatively regulated by PDX1 and confers
metastatic properties to PDA cells (Chen et al. 2007; Bai-
ley et al. 2016). Our data support the possibility of dual-
targeting PDX1 and MYC in PDX1-dependent tumors as
a viable therapeutic opportunity for the PDA patients.
In summary, our findings point to PDX1 as a context-de-
pendent mediator of PDA initiation and progression.
Based on our comprehensive analysis, it is evident that
to define PDX1 as an entirely pro- or anti-cancer factor
is naïve, and, without further understanding its diverse
functions, treating it as a therapeutic target, as has been
proposed (Yu et al. 2016), is premature. Future studies
are needed to identify how PDX1 might interact with
divergent sets of coregulators to modulate critical aspects
of cancer formation. Unraveling the temporal activities of
PDX1 should provide important insights into subtype-
specific disease vulnerabilities that can be targeted for per-
sonalized therapeutic intervention.
Materials and methods
Mouse lines
The followingmice strainswere used: Ptf1aCre, Ptf1aCreERTM, and
Pdx1f/f (Gannon et al. 2008; Roy and Hebrok 2015); KrasLSL-G12D,
PDX1-Cre, and Trp53R172H (gifts of David Tuveson, Cold Spring
Harbor Laboratory); and Trp53f/f, R26RLSL-YFP, and NOD scidγ
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(purchased from the Jackson Laboratory). Mice were crossed on a
mixed background. The University of California at San Francisco
and University of Michigan Institutional Care and Use of
Animals Committees (IACUCs) approved all of the mouse
experiments.
RNA-seq for acinar cells
RNA was harvested using the RNEasy Plus kit (Qiagen, 74136)
and assessed for quality using the TapeStation (Agilent). Samples
with an RNA integrity number of ≥8 were rRNA-depleted using
RiboMinus (Invitrogen, K1550-04). rRNA-depleted samples were
prepared using the TruSeq mRNA sample preparation version 2
kit (Illumina, RS-122-2001 and RS-122-2002). The entire fraction
of 0.1–3 µg of rRNA-depleted total RNAwas fragmented and cop-
ied into first strand cDNAusing reverse transcriptase and random
primers. cDNA 3′ ends were adenylated, and adapters were ligat-
ed. One of the adapters had a 6-nucleotide barcode that was
unique for each sample, allowing us to multiplex in a HiSeq
flow cell (Illumina). Products were purified and enriched by
PCR to create the final cDNA library. Libraries were checked
for quality and quantity by TapeStation (Agilent) and quantita-
tive PCR using a library quantification kit for Illumina platforms
(Kapa Biosystems, KK4835). They were clustered on the cBot
(Illumina) and sequenced 24 samples per lane on six lanes of a
50-cycle single-end HiSeq 4000. HiSeq control software version
3.3.52 was used according to manufacturer’s protocols. Demulti-
plexing and FastQ file generation were done using bcl2fastq ver-
sion 2.17.1.14.
ChIP-seq
Chromatinwas prepared from isolated acinar cells or cell lines us-
ing the truChIP chromatin-shearing reagent kit (Covaris,
520154). Chromatin was sheared in 1-mL millitubes (Covaris,
520135) using a Covaris S200 (5% duty cycle, intensity of 4,
200 cycles per burst, for 8 min) to obtain chromatin fragments
100–700 base pairs in length. Fifty micrograms of fragmented
chromatin was incubated overnight with 2.5 μL of rabbit anti-
PDX1 antibody (Millipore, 07-696). Complexes were isolated us-
ing 50 μL of Dynabeads (Invitrogen, 10004D) previously blocked
with 1 mg/mL BSA. Two nanograms of immunoprecipitated
DNAwas prepared as a standard Illumina library using the Thru-
PLEX DNA-seq kit (Rubicon) according to the manufacturer’s
protocol. Samples were PCR-amplified and pooled. Final libraries
were checked for quality and quantity by TapeStation (Agilent)
and quantitative PCR using Kapa’s library quantification kit for
Illumina sequencing platforms (Kapa Biosystems, KK4835).
They were clustered on the cBot (Illumina) and sequenced three
samples per lane on a 50-cycle single-end HiSeq 2000 in high-out-
put mode using version 3 reagents. The raw reads were aligned to
mm10 assembly by Bowtie1 using unique mapping mode, mean-
ing the reads that could be mapped to more than one location
were discarded. MACS2 was used for transcription factor peak
calling, and then blacklist islands were removed from the peaks.
Peaks were annotated by HOMER for their locations relative to
nearby genes.
BrU-seq
BrU-seq on “grow out” cells treatedwith dox andNB490 sh1 cells
left untreated or treated with dox for 48 h was performed as de-
scribed previously (Paulsen et al. 2014). Briefly, BrU (Aldrich)
was added to the culture medium of cells to a final concentration
of 2 mM, and cells were then incubated for 30 min at 37°C. Cells
were lysed in TRIzol reagent (Invitrogen), and cell lysates were
scraped off and collected. Total RNA was isolated, and BrU-la-
beled RNA was captured by incubation of isolated total RNA
with anti-BrdU antibodies (BD Biosciences) conjugated to mag-
netic Dynabeads (Invitrogen) under gentle agitation for 1 h at
room temperature. cDNA libraries were prepared from isolated
Bru-labeled RNA using the Illumina TruSeq library kit and se-
quenced using Illumina HiSeq sequencers at the University of
Michigan DNA Sequencing Core. Sequencing and read mapping
were carried out as described previously (Paulsen et al. 2014).
Acinar cell explants
Pancreata were harvested, washed twice in Hank’s buffered salt
solution (HBSS), minced, and incubated with 0.2 mg/mLCollage-
nase P (Roche, 11249002001) for 15 min at 37°C. Tissue was
washed three times in HBSS containing 5% FBS and filtered
through 500-μm and 105-μm polypropylene mesh (Spectrum Lab-
oratories, 106436 and 106418). Filtrate was centrifuged through
30%FBS in HBSS and resuspended in completeWaymouthmedi-
um (1× Waymouth MB 752/1 medium, 50 mg/mL gentamycin,
0.4 mg/mL soybean trypsin inhibitor, 1 mg/mL dexamethasone).
For RNA-seq experiments, suspensionwas plated in nonadherent
plates, treated with 50 ng/mL TGFα, and maintained at 37°C in a
5%CO2 atmosphere. Acinar cells used in transdifferentiation as-
says were plated in 2.5 mg/mL bovine collagen I (Trevigen, 3442-
050-01). Collagen/cell mixture was overlaid with complete Way-
mouthmedium supplementedwith 1.9 pmol/L cerulein, changed
the next day and every other day thereafter.
Human subjects
The PDAC tissue microarray has been described previously
(Nguyen Kovochich et al. 2013) and included three separate 1.0-
mm tumor cores from each of 145 treatments: naïve or AJCC
stage I or II PDACs resected at University of California at Los An-
gelesMedical Center from 1990 to 2005. All work was performed
with prior institutional review board approval. Human subjects
used for RNA-seq-based analysis have been described previously
(Bailey et al. 2016).
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